Abstract:Topic: Retinopathy of prematurity (ROP) is a severe retinal vascular disorder affecting preterm infants, potentially leading to retinal detachment and blindness. This review aims to elucidate the relationship between systemic VEGF levels and ROP. Clinical relevance: This systematic review aims to consolidate evidence from available studies to guide future research and inform clinical practice. In particular, the role of circulating VEGF-A levels in predicting ROP onset and progression, and evaluating the impact of anti-VEGF therapy on these levels, is crucial in ensuring efficacy and safety in patient care. Methods: Scopus and PubMed were searched to identify studies investigating circulating VEGF-gene products in ROP patients using immunologic assays. Two authors independently screened the literature and extracted data, employing a random-effects meta-analysis to compare VEGF levels as the ratio of means between ROP patients and controls before and after treatment, heterogeneity was reported by I2-statistics. Risks of bias and publication bias were assessed using Quality Assessment of Diagnostic Accuracy Studies-2 and funnel plots/Egger's tests, respectively. Results: Out of 941 papers, 54 were included, with 26 providing posttreatment data and 31 providing biomarker data. Findings show a significant decrease in VEGF-A levels in the first week after ROP treatment (ratio of means [95% confidence interval] 0.34 [0.25-0.45], I2 = 97%, 17 publications). Anti-VEGF therapy showed a significantly more pronounced decrease (0.31 [0.25-0.38], I2 = 40%, 7 publications) than laser treatment in the first week after treatment (0.77 [0.61-0.97], I2 = 42%, 2 publications, subgroup difference, P < 0.01), among studies with a low risk of bias. Serum samples demonstrated a more marked decrease in VEGF-A than plasma (subgroup difference P < 0.01). However, the use of blood VEGF-A concentration as a biomarker for ROP prediction has shown inconsistent trends. The risk of bias mainly stems from unclear patient selection and lack of sample timing or analytical method details. Conclusion: While anti-VEGF treatment significantly reduced blood VEGF-A levels in the first week post-ROP treatment, blood VEGF-A levels did not consistently predict ROP development. Heterogeneity in the results underscores the need for optimized analytical methods and emphasizes the importance of considering individual variation in VEGF-A concentrations independent of ROP diagnosis. Financial disclosures: The author(s) have no proprietary or commercial interest in any materials discussed in this article.

Expression of Total Vascular Endothelial Growth Factor and the Anti-angiogenic VEGF 165 B Isoform in the Vitreous of Patients with Retinopathy of Prematurity.

Expression of pro- and anti-angiogenic isoforms of VEGF in the mouse model of oxygen-induced retinopathy.

Changes in Vitreous VEGF, Bfgf and Fibrosis in Proliferative Diabetic Retinopathy after Intravitreal Bevacizumab.

Inhibition of Neovascularization and Expression Shift of Pro-/Anti-Angiogenic Vascular Endothelial Growth Factor Isoforms after Intravitreal Bevacizumab Injection in Oxygen-Induced-Retinopathy Mouse Model

Anti-vascular endothelial growth factor treatment for retinopathy of prematurity

Redundant Mechanisms for Vascular Growth Factors in Retinopathy of Prematurity in Vitro

Evaluation of Retinal Vascularization in Retinopathy of Prematurity Regressed after Intravitreal Ranibizumab Monotherapy or Without Treatment Based on Fluorescein Angiography

Serum Vascular Endothelial Growth Factor Levels Before and after Intravitreous Ranibizumab Injection for Retinopathy of Prematurity

Long-term surgical outcomes and prognostic factors for advanced-stage retinopathy of prematurity after vitrectomy

The Expression of Vascular Endothelial Growth Factor in the Retina of Rabbit with Retinal Vein Occlusion

The Analysis of Foveal Microvascular Anomalies in Retinopathy of Prematurity after Anti-Vascular Endothelial Growth Factor Therapy Using Optical Coherence Tomography Angiography

Application by Intravitreal and Topical Instillation

Foveal Structure Changes in Infants Treated with Anti-Vegf Therapy or Laser Therapy Guided by Optical Coherence Tomography Angiography for Retinopathy of Prematurity.

Apelin in epiretinal fibrovascular membranes of patients with retinopathy of prematurity and the changes after intravitreal bevacizumab.

Vascular Endothelial Growth Factor Plasma Levels Before and after Treatment of Retinopathy of Prematurity with Ranibizumab

Circulating VEGF-A Levels in Relation to Retinopathy of Prematurity and Treatment Effects: A Systematic Review and Meta-Analysis

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Reduced Expression of Erythropoietin After Intravitreal Ranibizumab in Proliferative Diabetic Retinopathy Patients—Retrospective Interventional Study

Efficacy of Aflibercept Treatment and its Effect on the Retinal Perfusion in the Oxygen-Induced Retinopathy Mouse Model of Retinopathy of Prematurity

Nitric oxide and VEGF expression in the ischemic-hypoxic retinopathy

Vascular development analysis: a study for tertiary anti-vascular endothelial growth factor therapy after second reactivation of retinopathy of prematurity